by Dr. Giovanini Coelho 

Dr. Capeding led the first Phase 3 trial ever completed for a dengue vaccine candidate.

This blog was originally posed on the Dengue Vaccine Initiative website
 
This year’s Americas Dengue Prevention Board (DPB)

In a new editorial published in PLOS NTDs, “The NTDs and Vaccine Diplomacy in Latin America: Opportunities for United States Foreign Policy,” Sabin Vaccine Institute (Sabin) President Dr.

Titled, “New chapter unfolding in the fight against dengue with an unwritten ending,” the Dengue Vaccine Initiative’s (DVI) editorial just published in the October issue of Transactions

With the slogan “Immunization for a healthy future. Know, Check, Protect” WHO reminds us this week that vaccines prevent 2-3 million deaths each year. Just imagine this: 2 to 3 million lives. This equals the populations of countries like Mongolia or Botswana.  

More than half of the world’s population is at risk of contracting diseases carried by small organisms like mosquitoes, snails and sand flies.

In a new editorial published in PLOS NTDs, Sabin Vaccine Institute president Dr.